More and more archives and databases, including psychiatric hospital records, are being digitized for preservation, but this can present privacy risks from hacking, cautioned King Davis, PhD, faculty member, University of Texas at Austin School of Information.
Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, describes how his team built a predictive algorithm using machine learning to predict the development of posttraumatic stress disorder (PTSD).
The upfront prices of potentially curative therapies are terrifying to commercial payers and government payers alike. A panel on the last day of ISPOR 2019 discussed these issues in a session called, “Is Affordability Driving a Need to Revolutionize Drug Pricing?”
Eleanor M. Perfetto, PhD, MS, senior vice president of Strategic Initiatives for the National Health Council, discusses criticisms of the quality-adjusted life year (QALY) and what factors the measure does not take into account.
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the benefits of real-world evidence (RWE) for measuring end points, as well as the challenges posed by variability in clinical practice.
Current diagnostic tools, such as the Diagnostic and Statistical Manual of Mental Disorders, rely on symptoms to diagnose psychiatric diseases, but using biological measures instead could provide a more reliable, valid method of classifying these syndromes, said Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Through OneOncology, we will be able to identify best practices and support patients throughout the continuum of care, explained Jeff Patton, MD, chief executive officer of Tennessee Oncology.
During ISPOR 2019 annual meeting, a session featured biosimilar experts who reviewed the current state of affairs and various challenges related to uptake, while also sounding some notes of optimism.
The 175th Annual Meeting of the American Psychiatric Association featured a session on how cultural and ethnic differences could affect reponses to drugs.
Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services, discusses how freestanding emergency departments can be utilized in the move toward value-based care.
Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses lessons learned and best practices that have emerged as a result of different approaches to value assessment.
At ISPOR 2019, the concept of real option value—paying for treatment that might keep a patient alive long enough to try a future improved therapy—was discussed.
Representatives from different parts of the healthcare system, as well as an outside observer, weighed in on whether the reports issued by the Institute for Clinical and Economic Review (ICER) are taking away patient choice.
It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.
Studies presented in posters at the 175th Annual Meeting of the American Psychiatric Association demonstrated that the combination of olanzapine and samidorphan kept weight gain below levels typically seen in commonly used antipsychotics.
Efficacy is the primary factor in patients’ decisions to take antipsychotic medications, but weight gain is an important side effect that can also impact those decisions, explained Adam Simmons, director of clinical program management, Alkermes. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association, where he presented on the investigational drug ALKS 3831.
The poll by the American Psychiatric Association found that young men were especially reluctant to seek mental health care from their employers, even though most workers, especially young ones, said they felt willing to discuss mental health in the workplace.
Panelists at a session of the ISPOR 2019 annual meeting discussed the good and the bad about the quality-adjusted life-year (QALY) metric from their various perspectives.
While there are consequences of a 6-month episode of care under the Oncology Care Model (OCM), there will be trade-offs with any time window, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the need for more creative methods for value assessment, as well as how one-time, high-cost therapies make it harder to determine value.
Daniel Mullins, PhD, discusses what trends he expects to see in coming years regarding value in healthcare.
The American Journal of Psychiatry published one of the studies that led to approval of one of the most anticipated therapies in years: esketamine for treatment-resistant depression.
A coordinated specialty care model can most effectively address early psychosis, but it’s also important to involve the patient and their family members when making treatment decisions, according to Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University.
Medical futurist Daniel Kraft, MD, implored his audience of healthcare stakeholders attending the ISPOR 2019 annual conference to consider the different ways that technology disruption can improve care away from what he called “sick care,” while moderator Clifford Goodman, PhD, of The Lewin Group, moderated a panel that followed about the potential and pitfalls of disruption in healthcare.
Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine, explained how the stigma surrounding mental health issues can cause delays in treatment, but the increased discussion of mental health on social media may make young people become more comfortable with discussing their experiences and seeking help.
Lori Raney, MD, principal, Health Management Associates, explained that integrating mental health care into primary care settings can eliminate the need for a referral and potentially avoid stigmatization, but there still needs to be a better payment model for integrated care.
Pharmacy benefit managers (PBMs), have historically been a black box for those paying into them, partly because medications are confusing, explained Martin Makary, MD, MPH, a surgical oncologist and chief of the Johns Hopkins Islet Transplant Center.
A discussion with University of California at Berkeley sociologist Arlie Hochschild, PhD, author of the best-seller Strangers in Their Own Land: Anger and Mourning on the American Right, addressed how social psychiatry can help bridge the current political divide.
The 175th Annual Meeting of the American Psychiatric Association, meeting in San Francisco, California, featured research about loneliness among minority women at midlife.
Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, explained why it’s important to diagnose and treat concurrent substance use disorders and mental illnesses at the same time.
